Evaluating the Medtronic Avalus Ultra aortic valve for heart valve disease

Avalus Ultra Post-Approval Study (PAS)

This study is testing the Medtronic Avalus Ultra aortic valve to see if it is safe and effective for people with aortic valve disease.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 150 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Medtronic Cardiac Surgery (industry)
• Locations: 12 sites (Hartford, Connecticut and 11 other locations)
• Trial ID: NCT06506903 on ClinicalTrials.gov

What this trial studies

This study aims to assess the safety and effectiveness of the Medtronic Avalus Ultra aortic valve bioprosthesis in patients suffering from aortic valve disease. It is a prospective, multi-center, single-arm, interventional study that will involve approximately 150 subjects across various locations in the United States. Participants will receive the valve implant and will be monitored for one year post-procedure to evaluate outcomes.

Who should consider this trial

Good fit: Ideal candidates include individuals with moderate or greater aortic stenosis or regurgitation who require aortic valve replacement.

Not a fit: Patients with mild aortic valve disease or those who do not require valve replacement may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new effective treatment option for patients with aortic valve disease.

How similar studies have performed: Other studies evaluating bioprosthetic valves have shown promising results, indicating potential success for this approach.

Eligibility criteria

Inclusion Criteria

Subjects must meet the following criteria to be included in the study:

1. Subject has moderate or greater aortic stenosis or regurgitation, and there is a clinical indication for replacement of their native or prosthetic aortic valve with a bioprosthesis, with or without concomitant procedures, which are limited to any of the following:

   * Atrial fibrillation (AF) ablation
   * Ascending aortic aneurysm or dissection repair or replacement, with or without circulatory arrest
   * Coronary artery bypass graft (CABG)
   * Surgical management of the left atrial appendage (LAA)
   * Patent foramen ovale (PFO) closure
   * Resection of a sub-aortic membrane not requiring myectomy
2. Subject is geographically stable and willing to return to the implanting site for all follow-up visits
3. Subject is of legal age to provide informed consent
4. Subject has been adequately informed of risks and requirements of the study and is willing and able to provide informed consent for participation in the study

Exclusion Criteria

Subjects who meet any of the following criteria will not be eligible for participation in the study:

1. Subject has a pre-existing prosthetic valve or annuloplasty device in another position or requires replacement or repair of the mitral, pulmonary, or tricuspid valve
2. Subject has had a previous implant and then explant of the Avalus Ultra aortic valve bioprosthesis within the Avalus Ultra Post-Approval Study
3. Subject presents with active endocarditis, active myocarditis, or other systemic infection
4. Subject has a known hypersensitivity to contrast media that cannot be adequately premedicated
5. Subject has a known hypersensitivity to platinum, iridium, or tantalum
6. Subject has an anatomical abnormality that would increase surgical risk of morbidity or mortality, including:

   * Acute Type A aortic dissection
   * Ventricular aneurysm
   * Porcelain aorta
   * Hostile mediastinum
   * Hypertrophic obstructive cardiomyopathy
   * Documented pulmonary hypertension (systolic \>60mmHg)
7. Subject has a non-cardiac major or progressive disease with a life expectancy of less than 1 year. These conditions include but are not limited to:

   * Child-Pugh Class C liver disease
   * Terminal cancer
   * End-stage lung disease
8. Subject has renal failure, defined by dialysis therapy or glomerular filtration rate (GFR) \<30 mL/min/1.73 m2
9. Subject has active or untreated hyperparathyroidism
10. Subject is participating in another investigational device or drug trial (not including registries)
11. Subject is pregnant, lactating, or planning to become pregnant during the study period
12. Subject has a documented history of substance (drug or alcohol) abuse
13. Subject has greater than mild mitral valve regurgitation or greater than mild tricuspid valve regurgitation as assessed by echocardiography
14. Subject has systolic ejection fraction (EF) \<20% as assessed by echocardiography
15. Subject has Grade IV diastolic dysfunction
16. Subject has documented bleeding diatheses
17. Subject has had an acute preoperative neurological deficit or myocardial infarction and has not returned to baseline or stabilized ≥30 days prior to implant
18. Subject requires emergency surgery

Where this trial is running

Hartford, Connecticut and 11 other locations

• Hartford Hospital — Hartford, Connecticut, United States (RECRUITING)
• University of Florida Shands — Gainesville, Florida, United States (RECRUITING)
• Emory Saint Joseph's — Atlanta, Georgia, United States (RECRUITING)
• WellStar Kennestone Hospital — Marietta, Georgia, United States (RECRUITING)
• Northwestern Memorial Hospital — Chicago, Illinois, United States (RECRUITING)
• University of Michigan Health System - University Hospital — Ann Arbor, Michigan, United States (RECRUITING)
• Mayo Clinic — Rochester, Minnesota, United States (RECRUITING)
• St. Joseph's Hospital Health Center — Syracuse, New York, United States (RECRUITING)
• ProMedica Toledo Hospital — Toledo, Ohio, United States (RECRUITING)
• Heart Hospital of Austin — Austin, Texas, United States (RECRUITING)
• Houston Methodist Hospital — Houston, Texas, United States (RECRUITING)
• Swedish Medical Center Cherry Hill — Seattle, Washington, United States (RECRUITING)

Study contacts

• Principal investigator: Juan Crestanello, MD — Mayo Clinic
• Study coordinator: Maggie Haltvick

Conditions: Aortic Valve Disease